Palisade Bio entered into a collaboration with Strand Life Sciences is aimed at advancing precision medicine for ulcerative colitis (UC) therapy and provides the company access to advanced ...

The reverse stock split was approved by Palisade Bio’s stockholders at the special meeting of stockholders held on October 4, 2022. The reverse stock split is primarily intended to increase the ...

Palisade Bio said the findings demonstrated PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both ... Why Palisade Bio Stock Is Soaring Today.

Palisade Bio (PALI) stock soared 150% Monday in the wake of news that it has cancelled a proposed offering and plans to conduct a reverse stock split instead. Read more here.

Palisade Bio has ended development of its lead and only drug in one of two potential indications after it ... Palisade's stock collapses as sole asset flunks phase 2 GI trial in post-surgery patients.

Palisade Bio Inc.’s stock PALI more than doubled in price on Wednesday, after the company announced a licensing agreement with privately held Giiant Pharma Inc. Carlsbad, Calif.-based Palisade ...

Palisade Bio (PALI) stock soared as high as 180% after the biotech announced a licensing deal with Giiant Pharma for multiple drug candidates to treat IBD. Read more here.

Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and ...